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Abstract
There is a long-standing controversy in the literature as to whether sickle-cell trait (SCT) should
be viewed as a benign carrier state or as an intermediate disease phenotype. Because SCT is
routinely detected by neonatal screening for sickle-cell disease, it becomes imperative that
consensus on this issue be achieved in order to provide the best medical advice to affected
individuals. The issue of selective screening in the post-neonatal period was thrust into the
limelight recently by the National Collegiate Athletic Association’s recommendation that its
member colleges and universities test student-athletes to confirm their carrier status if not already
known. The stated goal of this recommendation was to prevent exercise-related sudden death in
athletes with SCT. We review some of the reported complications of SCT for which new
information has emerged, focusing particularly on venous thromboembolism and renal
manifestations.
Introduction
Sickle-cell trait (SCT) is the term used to describe the presence in an estimated 300 million
individuals worldwide of a heterozygous glutamic acid-to-valine substitution in the β-globin
gene on chromosome 11 (HbAS). In the United States, 6% to 9% of the African-American
population and 0.01% to 0.05% of the remaining population (primarily those of Arab,
Indian, Hispanic, and Mediterranean descent) are carriers of the βs mutation.1,2 In aggregate,
this equates to approximately 3 million people. It has been appreciated for almost half a
century that the high prevalence of HbAS and other hemoglobinopathy carrier states reflects
the selection pressure afforded by protection of affected subjects against falciparum
malaria.3 Protection appears to be quite specific for this organism, and it seems to mitigate
the development of severe complications rather than mild, symptomless parasitemia.4 The
molecular, cellular, and immunologic basis for the protective effect of SCT continues to be
debated, but given the estimated 1 million annual deaths from malaria—primarily in sub-
Saharan Africa—it remains a high-priority research area.
Early publications linked SCT to a wide variety of medical conditions,5 but many of these
studies were small case series or uncontrolled observational studies. Appropriate concerns
were raised about unwarranted stigmatization of sickle carriers, particularly considering that
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neonatal screening programs for sickle-cell disease (SCD) were being implemented at the
time.6 A more recent review7 revisited the current understanding of the complications of
SCT, listing them as: i) “definite”: renal medullary carcinoma, hematuria, renal papillary
necrosis, hyposthenuria, splenic infarction, exertional rhabdomyolysis, exercise-related
sudden death, and protection against severe falciparum malaria; ii) “probable”: complicated
hyphema, venous thromboembolism (VTE), fetal loss/demise, and low birth weight; iii)
“possible”: acute chest syndrome, asymptomatic bacteriuria in pregnancy, and proliferative
retinopathy; and iv) “unlikely”: stroke, cholelithiasis, priapism, leg ulcers, and avascular
necrosis of the femoral head. However, it should be noted that the assignment of
complications into these categories was not based on a systematic review of the literature,
and thus the importance of some of the conditions may have been overrated while others
might have been underrated. This review focuses on a few selected complications for which
new information has emerged and discusses practical clinical implications.
Screening for SCT: When and Why
The neonatal screening programs that are now established in all 50 states and the District of
Columbia have proven their effectiveness in the identification of SCD and the
administration of life-saving antibiotic prophylaxis in early childhood.8 However, universal
screening also “incidentally” identifies subjects with SCT. The success rate in notifying and
providing genetic counseling to individuals with SCT has been noted to vary considerably
by state.9 In addition, the changing demographics of the United States related to immigration
from parts of the world with a high prevalence of SCT have also contributed to the
recognition that only a minority of affected subjects are aware of their carrier status.
Currently, subjects with SCT in the United States may also be identified when they enlist in
the military (where screening has been employed for many years), when pregnant (although
screening of pregnant women is non-uniform), and occasionally when donating a kidney for
transplantation.10 In addition, for some years, college athletes have been screened for SCT
in some but not other educational institutions. In June 2009, the National Collegiate Athletic
Association (NCAA) recommended that all of its member colleges and universities test
student-athletes to confirm their carrier status if not already known. In 2007, a similar
recommendation was issued by the College of American Pathologists, although it did not
attract the same degree of attention. This controversial decision was precipitated by a
lawsuit filed against the NCAA by the family of a student-athlete who died in 2006 from
exertional rhabdomyolysis during football practice.
Exercise-Related Complications in SCT
During exercise, SCT appears to be a risk factor for sudden death and/or rhabdomyolysis,
particularly when the exercise is intense, occurs in suboptimally conditioned individuals, is
performed at high altitude, and especially when the subject is dehydated or hyperthermic.
This association has been recognized for several decades, but the best available
epidemiologic evidence comes from the military. Kark et al. demonstrated an approximately
30-fold increased risk of sudden death in black Army recruits with SCT, with an absolute
risk of sudden unexplained death of 32.2 per 100,000 in SCT, compared with those without
the βs gene, who had an absolute risk of 1.2 per 100,000.11 More seasoned servicemen did
not appear to be at the same high risk. The subsequent modification of drills and improved
attention to hydration status in recruits during boot camp appeared to reduce the rate of
SCT-related sudden death, although more recently, it has been on the rise again.12 The
pathophysiology underlying these complications in SCT is not known, but is probably
related (at least in part) to the hemorheological changes that can occur as a result of sickling
of SCT erythrocytes within intensely exercising muscle.13 Recently, it has also been
demonstrated that the skeletal muscle capillary structure in subjects with SCT may differ
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significantly from controls matched for fitness level.14 Specifically, muscle biopsies from
SCT volunteers manifested a higher proportion of larger (>10 μm) microvessels, with an
overall reduction of capillary density and degree of vascular tortuosity. Whether these
changes contribute to maldistribution of muscle perfusion that contributes to exercise-related
acidosis and rhabdomyolysis is unknown.
VTE
Although it has long been recognized that patients with SCD manifest laboratory evidence
of constitutive hyperactivation of coagulation and platelets,15 and although a resultant
tendency to develop VTE might be expected, the epidemiologic evidence to support this
hypothesis has been sparse until recently. Two studies have now reported an increased risk
of VTE in women with SCD during pregnancy and the postpartum period.16,17 Stein et al.
analyzed National Hospital Discharge Survey data to demonstrate a higher prevalence of
pulmonary embolism (but not deep vein thrombosis) in African-American patients with
SCD compared with those without SCD.18 With regard to SCT, a similar analysis of more
than 65,000 African-American males admitted to 13 Veterans Administration hospitals
demonstrated that 7.8% were carriers of the βs globin mutation, with no age-dependent
decrease in the frequency of SCT.1 These data, in keeping with others available in the
literature, suggest that SCT has little or no impact on overall life expectancy. Furthermore,
in this study, no difference in the frequency of any diagnosis was observed between those
patients with or without SCT, with the exception of “essential hematuria” (discussed below)
and pulmonary embolism. Among patients with the HbAA genotype, 1.5% received a
diagnosis of pulmonary embolism, compared with 2.2% of those with HbAS (p < 0.001).1
We utilized a case-control study of VTE in African Americans (the Genetic Attributes and
Thrombosis Epidemiology or GATE study19), based in Atlanta, to determine whether SCT
might be a risk factor for VTE. The GATE study included more than 500 hospitalized black
patients with a recently diagnosed first or recurrent episode of VTE between March 1998
and September 2005, and an equivalent number of controls recruited from local medical
clinics. The prevalence of SCT (6.2%) in the control group was similar to other African-
American populations in the southeastern United States. The risk of VTE was increased
approximately 2-fold among subjects with HbAS compared with those with HbAA (odds
ratio [OR] = 1.8; 95% confidence interval [CI] 1.2–2.9). More strikingly, the OR for
pulmonary embolism was 3.9 (95% CI 2.2–6.9).20 These results suggest a potentially novel
mechanism for thrombophilia in African Americans, in whom the risk of VTE is 30% to
40% higher than that in Caucasian Americans. In fact, given the 6% to 9% prevalence of
HbAS in the African-American community, our data suggest that the proportion of VTE
attributable to HbAS in this population is approximately 7% compared with an attributable
risk of about 3% for the prothrombin G20210A mutation in the white population.20 In a
follow-up study, we evaluated the effect of oral and other hormonal contraceptive use on
VTE risk in African-American women, and whether the association was modified by SCT.
As with other case-control studies that have primarily included subjects of European
descent, hormonal contraception was associated with about a 3-fold increased risk of VTE in
African-American women.21 Furthermore, although the numbers were relatively small, we
observed some evidence of synergy between SCT and hormonal contraception use, a finding
that requires confirmation in other larger studies.
Because certain plasma “pre-thrombotic” biomarkers such as D-dimer have been shown to
have predictive value in the assessment of future risk of primary VTE,22 it might be
reasonably asked whether baseline levels of D-dimer are elevated in healthy SCT subjects
compared with controls matched for race, age, and gender. In fact, such an association has
been previously reported,23 and is confirmed by our own data obtained in healthy
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ambulatory African-American subjects with SCT (C. Amin, unpublished data). Currently,
however, the mechanism(s) underlying the increased risk of VTE in SCT remains unknown.
Until further confirmation of the association between SCT and VTE is forthcoming,
widespread screening of any racial/ethnic group with VTE cannot be recommended. It is
also premature to conclude that women with SCT should be denied access to hormonal
contraceptive therapy in any situation. VTE in subjects with known SCT should be managed
according to accepted evidence-based recommendations, which have shown that with only a
few exceptions, the most important determinant of the duration of anticoagulation therapy is
whether the thrombosis occurred in a predictably high-risk situation (such as after surgery or
trauma) or if it was unprovoked.
Renal Complications
Renal abnormalities are among the most widely acknowledged complications of SCT.
Hematuria was first reported in SCT more than 50 years ago.24 It is thought to be the most
common manifestation of SCT, although its true incidence remains uncertain.7,25,26 Based
upon data from a large series of African-American patients admitted to Veterans
Administration hospitals, hematuria accounted for 4% of hospitalizations among those with
SCT, approximately twice the rate among those patients with a normal hemoglobin
phenotype.1 The renal medulla represents an acidotic environment characterized by low
oxygen tension and high interstitial osmolarity. As blood traverses the slow-moving circuit
of the medullary vasa recta, the hyperosmolar milieu may enhance dehydration of
erythrocytes, allowing sickling and probable vaso-occlusion and medullary
microinfarctions.25,26 Bleeding, which is typically painless, presents as microscopic or gross
bleeding and may be associated with renal papillary necrosis. Involvement of the left kidney
is more common due to its slightly larger size and higher venous pressure that results from
compression of the left renal vein by the aorta and superior mesenteric vein.25,26
Conservative management of bleeding with bed rest and aggressive hydration is usually
sufficient. In refractory cases, medical intervention with desmopressin or ε-aminocaproic
acid, or even invasive intervention with ureteroscopy or angiography, has been advocated.26
The same vascular abnormalities that cause hematuria from ischemia and microinfarction
also lead to the impairment of urinary concentration and even isosthenuria.
Microradiographs of the SCT kidney performed more than 30 years ago demonstrated
reduction and disruption of the vasa recta, the intricate vascular system of the kidney
responsible for generating an osmolar gradient.27 Although not as severe as those seen in
SCD, these vascular changes likely lead to the observed impairment of urinary concentration
in patients with SCT.27 This loss of urinary concentration with dehydration may be a
contributing factor in the development of rhabdomyolysis and sudden death related to
exercise in SCT.7,12,13,28 The degree of impairment of urinary concentration is also variable
among subjects with SCT, and may be related to the percentage of hemoglobin S, which in
turn is determined by the co-occurrence of an α-globin gene deletion(s).29,30 Thus, among
individuals with SCT, maximal achievable concentration of urine following administration
of intranasal desmopressin acetate ranges between 530 and 845 mOsm, and is inversely
correlated with the number of α-globin gene deletions.31 In the presence of two α-globin
gene deletions (HbS concentration ~29%), urine concentration is only moderately reduced,
while in those with no α-globin gene deletions (HbS concentration ~42%), the ability to
concentrate urine is maximally impaired.31
A rare but serious complication of SCT is renal medullary carcinoma. The original
description of this neoplasm was reported in a series of 34 patients, 33 of whom had SCT.32
It still remains the case that nearly all instances reported in the literature occur in patients
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with SCT.33 This aggressive malignancy occurs twice as commonly in males, with mean age
at presentation of 21 years. Chronic ischemia has also been implicated in the pathogenesis of
renal medullary carcinoma, where it has been proposed that constant regeneration of the
distal collecting duct epithelium gives rise to malignant transformation.26
Given the architectural and functional renal aberrations, it is biologically plausible that SCT
could be a risk factor for chronic kidney disease. In particular, SCT may augment the risk
associated with a primary condition such as hypertension or diabetes, which are commonly
implicated in chronic kidney disease in the African-American community. Among a cohort
of African-American patients with end-stage renal disease (ESRD) due to autosomal
dominant polycystic kidney, SCT was found in 6 of 12 (50%), compared with only 7.5% of
African-Americans with ESRD due to other causes.34 This study did not evaluate the
background prevalence of SCT among African Americans in the population from which
patients were drawn. The investigators did find that those patients with autosomal dominant
polycystic kidney and concomitant SCT developed ESRD nearly 10 years earlier than those
without SCT, suggesting that SCT might enhance the progression of renal disease.34
Microalbuminuria, an early marker of renal injury, has also been demonstrated to be more
common among patients with SCT, particularly among diabetic men.35,36 However, another
study in diabetics failed to demonstrate this association.37 More importantly, there have
been no studies addressing whether interventions typically employed for proteinuria, such as
pharmacological blockade of the renin-angiotensin-aldosterone system, are beneficial in
SCT.
We evaluated the prevalence of SCT among 188 African-American ESRD patients receiving
care at four dialysis units. In this cohort, nearly 15% of patients were found to have SCT. In
comparison, prevalence of SCT the local African-American population was only 7%, as
determined by the results of the North Carolina state newborn screening program.38 This
observation provides some support for the contention that SCT may indeed influence the
progression of renal disease. However, given the observational nature of the study in a
relatively confined population, it is possible that familial clustering could play a role in the
heightened prevalence noted. Additionally, SCT patients were noted to have been on
dialysis for a longer duration, raising the possibility that SCT could confer some survival
advantage that would also manifest as a higher proportion among ESRD patients.38,39 In
contrast to our findings, another study explored the influence of SCT in 376 African-
American diabetics using routine HgbA1C assays to identify patients expressing HbS.40
African-American non-HbAS patients and HbAS patients had similar estimated glomerular
filtration rates and prevalence of microalbuminuria. Using multivariate modeling, the
investigators noted no difference in the combined outcome of peripheral vascular disease,
retinopathy, and kidney failure.40 The absolute incidence of kidney failure in this population
was not reported, although it was presumably low given the mean estimated glomerular
filtration rate reported. Additionally, the cohort of African-American patients studied
included a high proportion with SCT (~29%), which may indicate some unique
characteristic of this cohort. The conflicting data from these two recent studies highlight the
need for larger, prospective studies to determine the possible contribution of SCT to ESRD.
Finally, SCT may also affect the clinical course of ESRD. Anemia is almost universal
among ESRD patients, and is routinely treated with erythropoiesis-stimulating agents
(ESAs). African-American ESRD patients require higher doses of ESAs to achieve similar
target hemoglobins as Caucasian patients.41 We recently examined whether the presence of
variant hemoglobins influences the required dose of ESAs in the setting of ESRD. Among
155 African-American ESRD patients receiving hemodialysis at the University of North
Carolina, the 24 with SCT and 10 with other hemoglobin variants (principally HbAC) were
three times as likely to be ESA resistant.42 With both a possible high prevalence and the
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potential to modify ESA therapy, knowledge of SCT status may become important in the
management of ESRD patients. However, these observations require confirmation (and
consensus regarding the underlying pathogenic mechanism) before they are adopted into
clinical practice.
Conclusions
Overall, the evidence suggests that SCT may be neither a completely benign carrier state nor
a true disease entity, but rather a risk factor for certain adverse outcomes that result from the
interplay between genetic and environmental influences. VTE and renal disease are among
the manifestations under reevaluation. At present, the findings from case-control studies
remain suggestive of an association with these outcomes but must be regarded as being far
from definitive. Until such time as these observations have been confirmed, expanding
screening efforts must be considered to be of little benefit. Nonetheless, with ongoing
newborn screening identifying individuals with SCT, furthering research to better
characterize the consequences of SCT is of paramount importance to providing better
counseling on any associated health risks.28,39
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